P2Y12-receptor inhibitor

From Aaushi
Jump to navigation Jump to search

Notes

More general terms

More specific terms

Additional terms

References

  1. Brilakis ES et al. Medical management after coronary stent implantation: A review. JAMA 2013 Jul 10; 310:189 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23839753
  2. Bellemain-Appaix A et al Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25954988 <Internet> http://www.bmj.com/content/349/bmj.g6269
  3. 3.0 3.1 3.2 Susman E. Genetic Testing Aids in Anticoagulant Selection in ACS. Personalized approach tied to clinically meaningful reduction in ischemic and bleeding events. MedPage Today. March 12, 2018 https://www.medpagetoday.com/meetingcoverage/acc/71722
    Ardissino D, et al A prospective, randomised, multicentre study of a pharmacogenomic approach to the selection of antiplatelet therapy in acute coronary syndromes. American College of Cardiology (ACC) 2018; Abstract 18-LB-18910-ACC.
    Notarangelo FM, Maglietta G, Bevilacqua P, et al Pharmacogenomic approach to selecting antiplatelet therapy in acute coronary syndromes: PHARMCLO trial. J Am Coll Cardiol. March 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29540324 <Internet> http://www.onlinejacc.org/content/early/2018/02/23/j.jacc.2018.02.029
  4. 4.0 4.1 Pereira NL et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PC randomized clinical trial. JAMA 2020 Aug 25; 324:761. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32840598 https://jamanetwork.com/journals/jama/fullarticle/2769725